Induction of revertant fibres in the mdx mouse using antisense oligonucleotides

Genetic Vaccines and Therapy

Volumn 4, Issue , 2006, Pages

  Fall, Abbie M ^a   Johnsen, Russell ^a   Honeyman, Kaite ^a   Iversen, Pat ^b   Fletcher, Susan ^a   Wilton, Stephen D ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b AVI BIOPHARMA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DYSTROPHIN; ISOPROTEIN; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG FORMULATION; DRUG SYNTHESIS; EXON; FEASIBILITY STUDY; GENE LOCATION; GENE TARGETING; GENETIC CODE; GENETIC TRANSCRIPTION; IMMUNOHISTOCHEMISTRY; MOUSE; MOUSE STRAIN; MUSCLE CELL; MUSCLE EXCITATION; MUSCULAR DYSTROPHY; NONHUMAN; NONSENSE MUTATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVERTANT; WESTERN BLOTTING;

EID: 33745438706     PISSN: 14790556     EISSN: 14790556     Source Type: Journal    
DOI: 10.1186/1479-0556-4-3     Document Type: Article

References (53)

1. Ahn AH, Kunkel LM: The structural and functional diversity of dystrophin. Nat Genet 1993, 3:283-291.
2. Love DR, Byth BC, Tinsley JM, Blake DJ, Davies KE: Dystrophin and dystrophin-related proteins: a review of protein and RNA studies. Neuromuscul Disord 1993, 3:5-21.
3. Hoffman EP, Brown RHJ, Kunkel LM: Dystrophin: the protein product of the Duchenne muscular dystrophy focus. Cell 1987, 51:919-928.
4. Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM: An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 1988, 2:90-95.
5. Collins CA, Morgan JE: Duchenne's muscular dystrophy: animal models used to investigate pathogenesis and develop therapeutic strategies. Int J Exp Pathol 2003, 84:165-172.
6. Hoffman EP, Morgan JE, Watkins SC, Partridge TA: Somatic reversion/ suppression of the mouse mdx phenotype in vivo. J Neurol Sci 1990, 99:9-25.
7. Sherratt TG, Vulliamy T, Dubowitz V, Sewry CA, Strong PN: Exon skipping and translation in patients with frameshift deletions in the dystrophin gene. Am J Hum Genet 1993, 53:1007-1015.
8. Klein CJ, Coovert DD, Bulman DE, Ray PN, Mendell JR, Burghes AH: Somatic reversion/suppression in Duchenne muscular dystrophy (DMD): evidence supporting a frame-restoring mechanism in rare dystrophin-positive fibers. Am J Hum Genet 1992, 50:950-959.
9. Fanin M, Danieli GA, Cadaldini M, Miorin M, Vitiello L, Angelini C: Dystrophin-positive fibers in Duchenne dystrophy: origin and correlation to clinical course. Muscle Nerve 1995, 18:1115-1120.
10. Burrow KL, Coovert DD, Klein CJ, Bulman DE, Kissel JT, Rammohan KW, Burghes AH, Mendell JR: Dystrophin expression and somatic reversion in prednisone-treated and untreated Duchenne dystrophy. CIDD Study Group. Neurology 1991, 41:661-666.
11. Uchino M, Tokunaga M, Mita S, Uyama E, Ando Y, Teramoto H, Miike T, Ando M: PCR and immunocytochemical analyses of dystrophin-positive fibers in Duchenne muscular dystrophy. J Neurol Sci 1995, 129:44-50.
12. Nicholson LV, Johnson MA, Bushby KM, Gardner-Medwin D, Curtis A, Ginjaar IB, den Dunnen JT, Welch JL, Butler TJ, Bakker E: Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 3. Differential diagnosis and prognosis. J Med Genet 1993, 30:745-751.
13. Danko I, Chapman V, Wolff JA: The frequency of revertants in mdx mouse genetic models for Duchenne muscular dystrophy. Pediatr Res 1992, 32:128-131.
14. Schatzberg SJ, Anderson LV, Wilton SD, Kornegay JN, Mann CJ, Solomon GG, Sharp NJ: Alternative dystrophin gene transcripts in golden retriever muscular dystrophy. Muscle Nerve 1998, 21:991-998.
15. Lu QL, Morris GE, Wilton SD, Ly T, Artem'yeva OV, Strong P, Partridge TA: Massive idiosyncratic exon skipping corrects the nonsense mutation in dystrophic mouse muscle and produces functional revertant fibers by clonal expansion. J Cell Biol 2000, 148:985-996.
16. Bulfield G, Siller WG, Wight PA, Moore KJ: X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci U S A 1984, 81:1189-1192.
17. Wilton SD, Dye DE, Blechynden LM, Laing NG: Revertant fibres: a possible genetic therapy for Duchenne muscular dystrophy? Neuromuscul Disord 1997, 7:329-335.
18. Mann CJ, Honeyman K, Cheng AJ, Ly T, Lloyd F, Fletcher S, Morgan JE, Partridge TA, Wilton SD: Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci U S A 2001, 98:42-47.
19. Mann CJ, Honeyman K, McClorey G, Fletcher S, Wilton SD: Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy. J Gene Med 2002, 4:644-654.
20. Wilton SD, Lloyd F, Carville K, Fletcher S, Honeyman K, Agrawal S, Kole R: Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. Neuromuscul Disord 1999, 9:330-338.
21. Lu QL, Mann CJ, Lou F, Bou-Gharios G, Morris GE, Xue SA, Fletcher S, Partridge TA, Wilton SD: Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med 2003, 9:1009-1014
22. van Deutekom JC, Bremmer-Bout M, Janson AA, Ginjaar IB, Baas F, den Dunnen JT, van Ommen GJ: Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum Mol Genet 2001, 10:1547-1554.
23. Fletcher S, Honeyman K, Fall AM, Harding PL, Johnsen RD, Wilton SD: Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide. J Gene Med 2006, 8:207-216.
24. Morgan JE, Beauchamp JR, Pagel CN, Peckham M, Ataliotis P, Jat PS, Noble MD, Farmer K, Partridge TA: Myogenic cell lines derived from transgenic mice carrying a thermolabile T antigen: a model system for the derivation of tissue-specific and mutation-specific cell lines. Dev Biol 1994, 162:486-498.
25. Wilton SD, Lim L, Dye D, Laing N: Bandstab: a PCR-based alternative to cloning PCR products. Biotechniques 1997, 22:642-645.
26. Wilton SD, Dye DE, Laing NG: Dystrophin gene transcripts skipping the mdx mutation. Muscle Nerve 1997, 20:728-734.
27. Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR: ESEfinder: a web resource to identify exonic splicing enhancers. Nucleic Acid Research 2003, Vol. 31:3568-3571.
28. Beggs AH, Hoffman EP, Snyder JR, Arahata K, Specht L, Shapiro F, Angelini C, Sugita H, Kunkel LM: Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. Am J Hum Genet 1991, 49:54-67.
29. England SB, Nicholson LV, Johnson MA, Forrest SM, Love DR, Zubrzycka-Gaarn EE, Bulman DE, Harris JB, Davies KE: Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 1990, 343:180-182.
30. Takeshima Y, Nishio H, Narita N, Wada H, Ishikawa Y, Minami R, Nakamura H, Matsuo M: Amino-terminal deletion of 53% of dystrophin results in an intermediate Duchenne-Becker muscular dystrophy phenotype. Neurology 1994, 44:1648-1651.
31. Winnard AV, Klein CJ, Coovert DD, Prior T, Papp A, Snyder P, Bulman DE, Ray PN, McAndrew P, King W, Burghes AH: Characterization of translational frame exception patients in Duchenne/Becker muscular dystrophy. Hum Mol Genet 1993, 2:737-744.
32. Fanin M, Freda MP, Vitiello L, Danieli GA, Pegoraro E, Angelini C: Duchenne phenotype with in-frame deletion removing major portion of dystrophin rod: threshold effect for deletion size? Muscle Nerve 1996, 19:1154-1160.
33. Passos-Bueno MR, Vainzof M, Marie SK, Zatz M: Half the dystrophin gene is apparently enough for a mild clinical course: confirmation of its potential use for gene therapy. Hum Mol Genet 1994, 3:919-922.
34. Heald A, Anderson LV, Bushby KM, Shaw PJ: Becker muscular dystrophy with onset after 60 years. Neurology 1994, 44:2388-2390.
35. Tokarz SA, Duncan NM, Rash SM, Sadeghi A, Dewan AK, Pillers DA: Redefinition of dystrophin isoform distribution in mouse tissue by RT-PCR implies role in nonmuscle manifestations of duchenne muscular dystrophy. Mol Genet Metab 1998, 65:272-281.
36. Thanh LT, Nguyen TM, Helliwell TR, Morris GE: Characterization of revertant muscle fibers in Duchenne muscular dystrophy, using exon-specific monoclonal antibodies against dystrophin. Am J Hum Genet 1995, 56:725-731.
37. Lopez AJ: Alternative splicing of pre-mRNA: developmental consequences and mechanisms of regulation. Annu Rev Genet 1998, 32:279-305.
38. Shapiro MB, Senapathy P: RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression. Nucleic Acids Res 1987, 15:7155-7174.
39. Dominski Z, Kole R: Selection of splice sites in pre-mRNAs with short internal exons. Mol Cell Biol 1991, 11:6075-6083.
40. Balvay L, Libri D, Fiszman MY: Pre-mRNA secondary structure and the regulation of splicing. Bioessays 1993, 15:165-169.
41. Neverov AD, Artamonova II, Nurtdinov RN, Frishman D, Gelfand MS, Mironov AA: Alternative splicing and protein function. BMC Bioinformatics 2005, 6:266.
42. Sironi M, Cagliani R, Pozzoli U, Bardoni A, Comi GP, Giorda R, Bresolin N: The dystrophin gene is alternatively spliced throughout its coding sequence. FEBS Lett 2002, 517:163-166.
43. Hastings ML, Milcarek C, Martincic K, Peterson ML, Munroe SH: Expression of the thyroid hormone receptor gene, erbAalpha, in B lymphocytes: alternative mRNA processing is independent of differentiation but correlates with antisense RNA levels. Nucleic Acids Res 1997, 25:4296-4300.
44. Cheng AM, Byrom MW, Shelton J, Ford LP: Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res 2005, 33:1290-1297.
45. Harding PL, Fall AM, Honeyman K, Fletcher S, Wilton S: AO design for splicing blockade of dystrophin pre-mRNA processing:. size does matter. Molecular Therapy 2006, Accepted:.
46. Errington SJ, Mann CJ, Fletcher S, Wilton SD: Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene. J Gene Med 2003, 5:518-527.
47. Iversen PL: Phosphorodiamidate morpholino oligomers: favorable properties for sequence-specific gene inactivation. Curr Opin Mol Ther 2001, 3:235-238.
48. Summerton J: Morpholino antisense oligomers: the case for an RNase H-independent structural type. Biochim Biophys Acta 1999, 1489:141-158.
49. Muntoni F, Mateddu A, Marchei F, Clerk A, Serra G: Muscular weakness in the mdx mouse. J Neurol Sci 1993, 120:71-77.
50. Sharp NJ, Kornegay JN, Van Camp SD, Herbstreith MH, Secore SL, Kettle S, Hung WY, Constantinou CD, Dykstra MJ, Roses AD, Bartlett RJ: An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. Genomics 1992, 13:115-121.
51. McClorey G, Moulton HM, Iversen PL, and SF, Wilton SD: Antisense oligonucleotide induced exon skipping restores dystrophin expression in a canine model of DMD. Gene Therapy 2006, Accepted:.
52. van Deutekom JC, van Ommen GJ: Advances in Duchenne muscular dystrophy gene therapy. Nat Rev Genet 2003, 4:774-783.
53. Aartsma-Rus A, Janson AA, Kaman WE, Bremmer-Bout M, van Ommen GJ, den Dunnen JT, van Deutekom JC: Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes ore sense. Am J Hum Genet 2004, 74:83-92.